Form 4 for TYRA Tyra Biosciences, Inc.
Accepted 2026-05-07 16:30:09 ET · period of report 2026-05-05 · accession 0001193125-26-212114 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-05-07 16:30 | 2026-05-05 | TYRA | Harris Todd | Pres, CEO, Dir | A - Grant | $0.00 | +79.0K | 1.44M | +6% | $0 |
| D | 2026-05-07 16:30 | 2026-05-05 | TYRA | Harris Todd | Pres, CEO, Dir | A - Grant | $0.00 | +265.0K | 265.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-05 | A | A | 79,000 | $0.00 | 1,437,631 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. (F2) Includes RSUs. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-05-05 | A | A | 265,000 | $0.00 | 265,000 | D | $33.93 · — to 2036-05-04 | 265,000 Common Stock | (F3) 1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |